Skip to Content

Baricitinib use while Breastfeeding

Drugs containing Baricitinib: Olumiant

Medically reviewed by Drugs.com. Last updated on April 27, 2021.

Baricitinib Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the use of baricitinib during breastfeeding. Most sources recommend that mothers not breastfeed while taking baricitinib. An alternate drug is preferred, especially while nursing a newborn or preterm infant. Based on the reported half-life of about 12 hours, baricitinib should be mostly absent from breastmilk 3 days after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Rheumatoid Arthritis) Adalimumab, Certolizumab Pegol, Etanercept, Infliximab, Tocilizumab

Substance Identification

Substance Name

Baricitinib

CAS Registry Number

1187594-09-7

Drug Class

Breast Feeding

Lactation

Antirheumatic Agents

Enzyme Inhibitors

Janus Kinase Inhibitors

JAK Inhibitors

Signal Transduction Inhibitors

Protein Kinase Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.